<DOC>
	<DOCNO>NCT01009073</DOCNO>
	<brief_summary>This three arm study determine maximum tolerate dose ( MTD ) ABT-263 administer combination erlotinib ( Arm A ) , determine maximum tolerate dose ( MTD ) ABT-263 administer combination irinotecan ( Arm B ) , evaluate safety ABT-263 monotherapy ( Arm C ) .</brief_summary>
	<brief_title>A Study Evaluating ABT-263 With Erlotinib , ABT-263 With Irinotecan , ABT-263 Monotherapy Cancer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Greater equal 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 . Female subject must surgically sterile , postmenopausal ( least 1 year ) , negative result pregnancy test . Female subject surgically sterile postmenopausal ( least 1 year ) non vasectomize male subject must practice least one method birth control . Arm A ( ABT263 Erlotinib ) B ( ABT263 Irinotecan ) require prior ABT263 exposure , however , Arm C ( ABT263 monotherapy ) , subject must complete least one dose ABT263 previous study . For Arm A ( ABT263 Erlotinib ) Arm B ( ABT263 Irinotecan ) , subject histologically and/or cytologically documented cancer irinotecan erlotinib determine appropriate therapy determine Investigator . For Arm C ( ABT 263 monotherapy ) , subject malignancy either relapse refractory standard therapy know effective therapy exists . Adequate bone marrow , renal hepatic function per local laboratory reference range follow : * Bone marrow : Absolute Neutrophil count ( ANC ) great equal 1,000/microliter ; Platelets great equal 100,000/mm raise 3rd power ( Greater equal 150,000/mm raise 3rd power irinotecan combination ) independent platelet transfusion within 3 month prior start study drug ; Hemoglobin great equal 9.0 grams/deciliter ; * Renal function : serum creatinine less equal 2.0 milligrams/deciliter calculate creatinine clearance great equal 50 milliliter/minute ; * Hepatic function enzyme : AST ALT less equal 3.0 multiply upper normal limit ( ULN ) institution 's normal range ; Bilirubin le equal 1.5 multiply ULN . Subjects Gilbert 's Syndrome may Bilirubin Greater 1.5 multiply ULN ; Subjects liver metastasis may AST ALT le equal 5.0 multiply upper limit normal ; * Coagulation : aPTT , PT exceed 1.2 multiplied ULN . Subjects neurologic symptom ( e.g. , visual problem , headache , seizure ) must document brain imaging ( MRI CT ) within 28 day prior first dose study drug . If imaging perform , subject negative subdural epidural hematoma . Subjects brain metastasis must clinically control symptom define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence CNS disease progression determine CT MRI within 28 day prior first dose study drug . Subject must voluntarily sign date inform consent , approve Independent Ethics committee ( IEC ) /Institutional Review board ( IRB ) , prior initiation screen studyspecific procedure . Subject active peptic ulcer disease hemorrhagic esophagitis/gastritis . Subject significant history cardiovascular disease ( e.g. , MI , thrombotic thromboembolic event last 6 month ) , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease opinion Investigator would adversely affect his/her participate study . Question regard inclusion individual subject direct Abbott Medical Monitor designee . Female subject pregnant breastfeeding . Subject test positive HIV ( due potential drugdrug interaction anti retroviral inhibitor ABT263 , well anticipate ABT263 mechanism base lymphopenia may potentially increase risk opportunistic infection potential drug drug interaction certain antiinfective agent ) . Subject exhibit evidence clinically significant uncontrolled condition ( ) include , limited : * active systemic fungal infection ; * diagnosis fever neutropenia within 1 week prior study drug administration . Subject receive follow anticancer therapy 14 day prior first dose study drug , recover less Grade 2 clinically significant adverse effect ( ) /toxicity ( ) previous therapy : * chemotherapy , immunotherapy , radiotherapy ; * hormonal ( exception hormone hypothyroidism estrogen replacement therapy [ ERT ] , agonists required suppress serum testosterone level [ e.g. , LHRH , GnRH , etc . ] subject prostate cancer stable dose 21 day prior first dose study drug ) ; * investigational therapy ABT263 , include target small molecule agent . Subject receive biologic agent antineoplastic intent within 30 day prior first dose study drug . Subject currently receive require anticoagulation therapy ( e.g. , warfarin dose ) drug herbal supplement affect platelet function , exception lowdose anticoagulation medication heparin use maintain patency catheter . Subject receive aspirin warfarin within 7 day prior first dose study drug . Subject consume grapefruit grapefruit product within 3 day prior first dose study drug . History hypersensitivity erlotinib polysorbate 80 drug ( applicable ABT 263 monotherapy ) . Received potent CYP3A inhibitor ( e.g. , ketoconazole ) within 7 day prior first dose study drug . Received ABT263 within 3 day prior first dose study drug ( applicable ABT263 monotherapy ) . In opinion Investigator , subject unsuitable candidate receive ABT 263 . Subject receive rifampin within 4 day prior first dose study drug Arm A ( ABT263 erlotinib ) Arm C ( ABT263 Monotherapy ) within 7 day prior first dose study drug Arm B ( ABT263 irinotecan ) . Subjects UGT1A1*28 7/7 homozygous Arm B ( ABT263 irinotecan ) study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>